Compounded Semaglutide: What It Is and Whether It Is Safe

Compounding is when a pharmacy prepares a drug itself, rather than dispensing a product manufactured under FDA's approval process.

When the copy contains the same active ingredient, in a similar strength and by the same route, as an approved drug, FDA calls it "essentially a copy" — unless the prescriber documents a significant difference for that specific patient, an exception covered below — and semaglutide vials made that way are exactly that.

Adding a second ingredient does not automatically avoid the rule: FDA gives semaglutide plus vitamin B12 as its own example of a combination it may consider an essentially copy.

Two consequences matter more than anything else in this article.

First, a compounded drug is not FDA-approved: FDA does not review it for safety, effectiveness or quality before it is sold.

Second, FDA's stated position is that compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug.

The mechanics — the 503A pharmacy track, the 503B outsourcing-facility track, and the paperwork behind the exception that remains in 2026 — are laid out in our compounded GLP-1 rules guide.

No — and FDA treats that claim itself as a warning sign.

FDA's telehealth red flags for GLP-1s include a seller claiming "the compounded drug is the same as an FDA-approved drug."

The two brand products are approved for different things.

Wegovy (semaglutide, Novo Nordisk) is FDA-approved, with diet and activity, to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, to reduce and maintain weight in adults and children 12 and older with obesity and in adults with overweight plus a weight-related condition, and — under accelerated approval — for noncirrhotic MASH with moderate-to-advanced liver fibrosis.

Ozempic is also semaglutide, but it is FDA-approved for type 2 diabetes, not for weight loss.

A compounded vial carries none of these approvals: FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, so there is no FDA-reviewed label behind the vial and no FDA verification of what is in it.

That is not a technicality — it is the reason the rest of this page exists.

Not on the basis that allowed it during the shortage.

FDA declared the semaglutide injection shortage resolved on February 21, 2025 — it had been in shortage since 2022 — and set deadlines: 503A pharmacies had until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop making essentially-copy products.

The deadlines held.

On April 24, 2025, the district court denied the preliminary injunction in the case challenging FDA over compounded semaglutide, so FDA said the 503A enforcement-discretion period had ended.

As of FDA's April 1, 2026 update, semaglutide appears on neither the drug shortage list nor the 503B bulks list, so outsourcing facilities generally may not compound semaglutide from bulk drug substance.

What remains is the narrow 503A path: a compounded copy can be made for an individual patient when the prescriber determines and documents that a change produces a significant difference for that patient — the "clinical difference" exception, which FDA's April 2026 update restates as an individual-patient, documented determination.

The review behind an approved drug — FDA checking it for safety, effectiveness and quality before it is sold — does not apply to a compounded vial, because FDA does not review these products.

The problems FDA has documented fall into three buckets: dose, ingredients and pharmacy.

Dose is the documented one.

In a July 2024 alert, FDA described compounded semaglutide overdoses, some requiring hospitalization: patients drew up five to 20 times the intended dose from multi-dose vials, and clinicians miscalculated milligram-to-"unit" conversions by five to 10 times, with confusion between milliliters, milligrams and "units" contributing.

The "unit" is the trap.

Compounded GLP-1 vials are often dosed in "units" on an insulin (U-100) syringe, where a unit is a volume mark, not a drug amount: 5 units is 0.05 mL, and how much semaglutide that is depends on the vial's concentration, which varies between compounders.

FDA's example: one provider meant to prescribe 0.25 mg (5 units) but prescribed 25 units — five times the intended dose — and the patient experienced severe vomiting.

In another case, 20 units were prescribed instead of 2.

Ingredients come second.

FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the ones used in the approved drugs, and that it is not aware of any lawful basis for using them in compounding.

It has also warned companies selling semaglutide falsely labeled "for research purposes" or "not for human consumption," and urges consumers not to buy such products.

Pharmacy quality is third.

FDA is aware of fraudulent compounded semaglutide whose labels name pharmacies that do not exist, or licensed pharmacies that did not actually make the product.

It advises not using any injectable GLP-1 that arrives warm or with insufficient refrigeration, and discarding a compounded multi-dose vial within 28 days of first use — even if medication remains and even if the compounder's instructions say longer — and using a new sterile needle and syringe for every dose.

One more limit on the record: FDA had received 990 adverse-event reports associated with compounded semaglutide as of May 31, 2026, and notes the count is likely underreported because 503A pharmacies are not required to report adverse events and causation cannot always be determined.

Report counts are not rates, so they do not tell you how likely a problem is — only that FDA is seeing these reports.

A clinic that does this properly will answer specific questions in writing.

These are the ones that map to what FDA has actually documented.

The reverse list matters just as much.

FDA's telehealth red flags include a seller claiming the compounded drug is the same as an FDA-approved drug, deep discounts that seem too good to be true, no screening and prescription by a licensed doctor, no doctor available for questions, label spelling errors or wrong pharmacy addresses, and a pharmacy name you suspect is fraudulent.

There is litigation in the background too: a law-firm alert reported that Novo Nordisk filed lawsuits against nine medical spas, clinics and pharmacies on May 30, 2024, alleging distribution of unauthorized semaglutide products, following earlier 2023 suits.

Those are allegations in filed cases, not findings against any clinic, and we have not confirmed them from court records.

And who may evaluate you and prescribe is state law — our who can prescribe GLP-1s guide covers how that works.

The FDA-approved alternative is brand-name semaglutide, and its maker now publishes self-pay cash prices for it.

Novo Nordisk's self-pay prices, listed via NovoCare Pharmacy or the Wegovy savings offer and read on October 16, 2026: Wegovy injection is $349 per month for the 0.25 mg to 2.4 mg doses and $399 per month for Wegovy HD 7.2 mg, and new patients pay $199 per month for the first two fills of the 0.25 mg and 0.5 mg doses through December 31, 2026.

Wegovy also now comes as a once-daily oral tablet, approved for weight reduction and cardiovascular risk reduction in adults.

Wegovy is prescription-only: it needs a valid prescription from a licensed prescriber, and FDA tells patients to fill prescriptions at state-licensed pharmacies.

Compounded vials are the open case: our research could not confirm any national price for compounded semaglutide.

Two cautions come with that.

FDA's telehealth red flags include deep discounts that seem too good to be true.

And the two prices are not like-for-like numbers — the brand price buys an FDA-reviewed product, while the compounded price buys one FDA has not reviewed for safety, effectiveness or quality.

For the approved product in full — approved uses, dosing, side effects and what drives its price — start with our semaglutide guide.

Two things separate a clinic worth asking from a checkout page.

The first is the prescriber: FDA's telehealth red flags include no screening and prescription by a licensed doctor, so expect a licensed prescriber who evaluates you and stays available for questions afterward — not an automatic approval.

The second is the pharmacy.

FDA tells patients to fill prescriptions at state-licensed pharmacies, and its fraud file includes products labeled with pharmacies that do not exist — so get the compounding pharmacy's name and state before you pay, and read the vial's label when it arrives.

If a shipment arrives warm or with insufficient refrigeration, FDA advises not using it.

Location changes the legal answer too: prescribing rules are set state by state, down to whether a nurse practitioner may prescribe independently.

That makes it worth checking a provider's credentials in your own state rather than assuming a national ad applies to you.